MedTrace Logo

Intravenous Hydromorphone for the Treatment of Acute Pain

NCT06949059 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-11-17

No results posted yet for this study

Summary

To observe the efficacy and safety of hydromorphone in the treatment of acute chest pain, and to explore the potential advantages of hydromorphone for analgesia in patients with acute chest pain, so as to provide more theoretical basis for individualized analgesia and rapid recovery in patients with acute chest pain.

Conditions

  • Acute Chest Pain

Interventions

DRUG

Hydromorphone

Hydromorphone 1mg was given intravenously and conventional treatment was performed at the same time.

Sponsors & Collaborators

  • Yichang Humanwell Pharmaceutical Co., Ltd., China

    collaborator INDUSTRY

  • The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-01
Primary Completion
2026-12-31
Completion
2027-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06949059 on ClinicalTrials.gov